G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
80 hedge funds and large institutions have $38.6M invested in G1 Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 29 reducing their positions, and 30 closing their positions.
391% more call options, than puts
Call options by funds: $982K | Put options by funds: $200K
17% less funds holding
Funds holding: 96 → 80 (-16)
25% less capital invested
Capital invested by funds: $51.5M → $38.6M (-$12.9M)
38% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 29
53% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$727K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$572K |
| 3 |
D.E. Shaw & Co
New York
|
+$510K |
| 4 |
Renaissance Technologies
New York
|
+$352K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.59M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.93M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$844K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$773K |
| 5 |
Millennium Management
New York
|
-$730K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$32.5K | -12,135 | Closed |
|
|
LIP
102
Lighthouse Investment Partners
Palm Beach Gardens,
Florida
| – | -$32K | -11,926 | Closed |
|
103
Janus Henderson Group
London,
United Kingdom
| – | -$28.3K | -10,566 | Closed |
|
|
DFCM
104
Dark Forest Capital Management
San Juan,
Puerto Rico
| – | -$22.9K | -8,536 | Closed |
|
|
PMEF
105
Point72 Middle East FZE
Dubai,
United Arab Emirates
| – | -$9.3K | -3,471 | Closed |
|
106
Legal & General Group
London,
United Kingdom
| – | -$6.32K | -2,358 | Closed |
|
107
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$5K | -2,026 | Closed |
|
|
BAM
108
Belpointe Asset Management
Reno,
Nevada
| – | -$5.36K | -2,000 | Closed |
|
|
ASN
109
Advisory Services Network
Atlanta,
Georgia
| – | -$536 | -200 | Closed |
|
GTHX Hedge Fund Activity: Q2 2023 in Review
80 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2023, worth a combined $38.6M — down 25% from $51.5M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of GTHX and 14 opened new positions — a net loss of 16 holders — while 29 trimmed existing stakes and 18 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $727K. The largest seller was Fidelity Investments, cutting an estimated $2.59M.
- 80 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2023, down from 96 in Q1 2023.
- Funds reported $38.6M of G1 Therapeutics, Inc. Common Stock stock for Q2 2023, down 25% quarter-over-quarter.
- 14 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2023 and 30 closed out, a net change of -16 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2023 was GSA Capital Partners, an estimated $727K added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2023 was Fidelity Investments, an estimated $2.59M sold.
Based on aggregated 13F filings for Q2 2023.